HAGEMANN ROBERT 4

What Happened

• Robert Hagemann, a director of Zimmer Biomet Holdings, Inc. (ZBH), was granted 317.369 phantom stock units on 2026-06-30. The units were awarded at $0.00 (no purchase price) as a deferred compensation award — not an open‑market buy or sale — and are derivative units rather than actual shares. There was no immediate cash transaction or market sale tied to this grant.

Key Details

• Transaction date: 2026-06-30
• Transaction type: Award/Grant of phantom stock units (Derivative, code A)
• Units granted: 317.369; grant price reported as $0.00
• Conversion/exercise: 1-for-1 (each unit converts on a one-for-one basis per filing)
• Settlement: Units will be settled in cash in five annual installments beginning within 60 days after the end of the calendar year in which the director stops serving (per footnote)
• Shares owned after transaction: Not specified in the filing
• Filing timeliness: No late‑filing indication in the provided details

Context

• These phantom units are a form of deferred compensation for non‑employee directors and do not represent immediate stock ownership or a market purchase. They are typically paid out in cash according to the plan’s schedule (here, five annual installments after director service ends), so they do not directly signal a buy or sell of company stock.